Shruti Chaturvedi, MBBS, MS, Assistant Professor of Medicine at Johns Hopkins explains the challenge of treating Jehovah’s Witnesses who have thrombotic thrombocytopenic purpura (TTP).
TTP is an ultra-rare hematologic condition due to reduced ADAMTS13 enzyme activity that leads to small but potentially deadly thrombotic events if not treated properly.
Standard treatment for TTP is plasma exchange. However, some populations such as Jehovah’s Witnesses prohibit the use of such practices. As such, alternative treatment options are necessary.
As Dr. Chaturvedi explains in this interview, these obstacles have created opportunities for the medical community to find solutions and it does appear that treatment without the use of plasma exchange is achievable in these patients.
To learn more about TTP and other hematologic conditions, click here.
